Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Intrahepatic Cholangiocarcinoma (Icc)

Shanghai 6th People's HospitalSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
73/ 100

Competitive context

38 Active assets in the Intrahepatic Cholangiocarcinoma (Icc) cohort.

Asset / SponsorPhaseRating
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
Durvalumab
West China Hospital
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B
Ipilimumab
TriSalus Life Sciences, Inc.
Phase 2B

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →